Cîrstea Diana
Main achievement
Instructor at Harvard Medical School. Physician at Massachusetts General Hospital
About
Diana Cîrstea is an oncologist from the Republic of Moldova, remarkable for her exceptional career in hematology and medical oncology in the United States of America. A graduate of Nicolae Testemițanu State University of Medicine and Pharmacy in Chișinău, where she obtained her Doctor of Medicine degree in 2000, she completed her training in dermatovenereology at the same institution in 2003. Her passion for multiple myeloma took shape in Dr. Noopur Raje's translational research laboratory, where she studied new therapies, including CDK inhibitors and agents targeting the PI3K/Akt/mTOR pathway, combined with conventional treatments. After her internal medicine residency at Mount Auburn Hospital in Cambridge, Massachusetts (2016), she completed fellowships in hematology/oncology at Boston Medical Center (2019) and in multiple myeloma research at Dana-Farber Cancer Institute. Board-certified by the American Board of Internal Medicine in hematology, medical oncology, and internal medicine, Dr. Cîrstea initially worked as a bone marrow transplant hospitalist at Dana-Farber/Brigham and Women’s Hospital, focusing on the care of patients with stem cell transplants and cellular therapies such as CAR-T. Since August 2022, she has been an oncologist at Mass General Brigham Cancer Center in Boston, within the Multiple Myeloma Program, where she treats adults with plasma cell disorders, including AL amyloidosis, monoclonal gammopathy, and multiple myeloma, and leads research in cellular immunotherapy. She is fluent in Romanian, Russian, and English, and is appreciated by patients for her professionalism, empathy, and ability to explain complex conditions in accessible terms, according to enthusiastic reviews on medical platforms. Although detailed information about her personal life is not publicly available, her contribution to hematologic oncology positions her as a role model for women in medicine, promoting excellence in the care of patients with rare and advanced diseases within the context of the top American healthcare system.
